\-\ Texto\\:\\ \ \(0\)\
\-\ exam\\:\\ thyroid\\ is\\ nontender\\,\\ left\\ lobe\\ visibly\\ larger\\ than\\ right\\,\\ soft\\ on\\ palpation\\,\\ normal\\ movement\\ during\\ swallow\\.\ \(0\)\
\-\ labs\\:\\ tsh\\ wnl\ \(0\)\
\-\ large\\ thyroid\\ nodule\\ with\\ fna\\ suspicious\\ for\\ papillary\\ vs\\ follicular\\ carcinoma\\.\\ \ \(0\)\
\-\ papillary\\ tc\\ ruled\\ out\\ by\\ intraoperative\\ frozen\\ section\\.\\ \\ definitive\\ diagnosis\\ unknown\\ at\\ time\\ of\\ case\\ compilation\\ pending\\ final\\ pathology\\ report\\.\ \(0\)\
\-\ this\\ patient\\ underwent\\ a\\ hemithyroidectomy\\ during\\ the\\ second\\ trimester\\.\\ \\ she\\ may\\ undergo\\ removal\\ of\\ her\\ remaining\\ thyroid\\,\\ followed\\ by\\ post\\-partum\\ radioiodine\\ ablation\\,\\ depending\\ on\\ the\\ final\\ pathology\\ report\\.\ \(0\)\
\-\ within\\ the\\ mid\\ to\\ lower\\ pole\\ of\\ the\\ left\\ lobe\\,\\ there\\ is\ \(0\)\
\-\ a\\ large\\ predominantly\\ solid\\ nodule\\ with\\ a\\ small\\ cystic\\ component\\ superiorly\\.\\ this\\ nodule\\ measures\\ 2\\.6\\ x\\ 2\\.1\\ x\\ 3\\.8\\ cm\\.\\ \\ no\\ microcalcifications\\.\\ \\ some\\ intranodular\\ vascularity\\,\\ primarily\\ peripheral\\.\\ \\ nodule\\ margins\\ are\\ smooth\\ and\\ well\\ defined\\.\ \(0\)\
\-\ thyroid\\ cancer\\,\\ probably\\ follicular\ \(0\)\
\-\ adenoma\ \(519\)\
\-\ \\ \\-macrofollicular\\ adenoma\ \(0\)\
\-\ \\ \\-microfollicular\\ adenoma\ \(0\)\
\-\ \\ \\-embryonal\\ adenoma\ \(0\)\
\-\ \\ \\-hurthle\\ cell\\ adenoma\ \(0\)\
\-\ \\ \\-atypical\\ adenoma\ \(0\)\
\-\ \\ \\-signet\\-ring\\ adenoma\ \(0\)\
\-\ carcinoma\ \(1182\)\
\-\ \\ \\-papillary\ \(0\)\
\-\ \\ \\-follicular\ \(0\)\
\-\ \\ \\-medullary\ \(2\)\
\-\ \\ \\-anaplastic\ \(0\)\
\-\ \\ \\-metastasis\ \(0\)\
\-\ \\ \\-thyroid\\ lymphoma\ \(0\)\
\-\ colloid\\ nodule\ \(0\)\
\-\ inflammatory\\ process\ \(22\)\
\-\ 27\\ y\\/o\\ woman\\ with\\ known\\ thyroid\\ asymmetry\\ x\\ 2\\ years\\,\\ presents\\ for\\ initial\\ prenatal\\ appointment\\.\\ \\ no\\ previous\\ workup\\ for\\ gland\\ asymmetry\\.\\ \\ patient\\ denies\\ hypo\\/hyperthyroid\\ symptoms\\.\\ \\ hx\\ negative\\ for\\ neck\\ irradiation\\.\ \(0\)\
\-\ this\\ case\\ highlights\\ the\\ differences\\ in\\ decision\\ making\\ for\\ the\\ pregnant\\ patient\\ with\\ a\\ newly\\ diagnosed\\,\\ asymptomatic\\ thyroid\\ nodule\\.\\ one\\ may\\ postpone\\ workup\\ in\\ the\\ euthymic\\ pregnant\\ patient\\ up\\ to\\ one\\ year\\ from\\ time\\ of\\ nodule\\ discovery\\ without\\ affecting\\ her\\ outcome\\.\\ \\ a\\ postpartum\\ workup\\ allows\\ for\\ additional\\ tests\\ such\\ as\\ radioactive\\ iodine\\ uptake\\,\\ although\\ these\\ tests\\ are\\ of\\ negligible\\ value\\ in\\ the\\ euthymic\\ patient\\.\ \(0\)\
\-\ if\\ the\\ nodule\\ is\\ worked\\ up\\ early\\ in\\ pregnancy\\ and\\ treatment\\ requires\\ surgical\\ removal\\ of\\ the\\ nodule\\,\\ the\\ patient\\ must\\ decide\\ whether\\ to\\ proceed\\ with\\ surgery\\ during\\ or\\ after\\ pregnancy\\.\\ \\ the\\ second\\ trimester\\ is\\ the\\ preferred\\ time\\ to\\ undergo\\ elective\\ procedures\\;\\ procedures\\ at\\ surgical\\ sites\\ remote\\ to\\ the\\ abdomen\\ are\\ considered\\ especially\\ low\\ risk\\ to\\ the\\ fetus\\.\\ \ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ however\\,\\ if\\ the\\ newly\\ diagnosed\\ patient\\ prefers\\ to\\ postpone\\ surgery\\ until\\ the\\ postpartum\\ period\\,\\ she\\ may\\ do\\ so\\ without\\ affecting\\ her\\ outcome\\,\\ even\\ if\\ she\\ has\\ thyroid\\ malignancy\\ with\\ local\\ lymph\\ node\\ mets\\.\ \(0\)\
\-\ \\ \\ \ \(31891\)\
\-\ the\\ pregnant\\ patient\\ who\\ requires\\ radioiodine\\ ablation\\ following\\ surgery\\ must\\ wait\\ to\\ undergo\\ ria\\ until\\ she\\ is\\ not\\ only\\ postpartum\\,\\ but\\ no\\ longer\\ breast\\ feeding\\ and\\ has\\ significanly\\ reduced\\ lactation\\.\\ \\ otherwise\\,\\ ria\\ may\\ increase\\ her\\ risk\\ of\\ breast\\ cancer\\ later\\ in\\ life\\.\ \(0\)\
\-\ \\ \\ \ \(31891\)\
\-\ references\\:\\ \ \(0\)\
\-\ the\\ american\\ thyroid\\ association\\ guidelines\\ taskforce\\:\\ revised\\ american\\ thyroid\\ association\\ management\\ guidelines\\ for\\ patients\\ with\\ thyroid\\ nodules\\ and\\ differentiated\\ thyroid\\ cancer\\;\\ thyroid\\ vol\\.\\ 19\\,\\ no\\.\\ 11\\,\\ 2009\\.\ \(0\)\
\-\ blum\\:\\ ultrasonography\\ of\\ the\\ thyroid\\;\\ thyroidmanager\\.org\\.\\ updated\\ january\\ 2009\\.\ \(0\)\
\-\ \\Â\\ \ \(347\)\
\-\ moosa\\ and\\ mazzaferri\\:\\ outcome\\ of\\ differentiated\\ thyroid\\ cancer\\ diagnosed\\ in\\ pregnant\\ women\\;\\ jcem\\ vol\\.\\ 82\\,\\ no\\.\\ 9\\.\\ printed\\ in\\ u\\.s\\.a\\.\\ copyright\\ \\Â\\©\\ 1997\\.\ \(0\)\
\-\ \\Â\\ \ \(347\)\
\-\ welker\\ and\\ orlov\\:\\ thyroid\\ nodules\\;\\ afp\\ vol\\.\\ 67\\,\\ no\\.\\ 3\\,\\ february\\ 2003\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ thyroid\\:\\ 0\\.4666037241716177\ \(0\)\
\-\ nodule\\:\\ 0\\.2636070178332203\ \(0\)\
\-\ adenoma\\:\\ 0\\.2070926753621785\ \(0\)\
\-\ pregnant\\:\\ 0\\.15578857606011778\ \(0\)\
\-\ the\\:\\ 0\\.1480892389605732\ \(0\)\
\-\ postpartum\\:\\ 0\\.13871063597126282\ \(0\)\
\-\ vol\\:\\ 0\\.13036873540506594\ \(0\)\
\-\ follicular\\:\\ 0\\.12723952456797144\ \(0\)\
\-\ postpone\\:\\ 0\\.11868868459488349\ \(0\)\
\-\ euthymic\\:\\ 0\\.11868868459488349\ \(0\)\
\-\ ria\\:\\ 0\\.11868868459488349\ \(0\)\
\-\ outcome\\:\\ 0\\.11861681666108191\ \(0\)\
\-\ workup\\:\\ 0\\.10485855470647727\ \(0\)\
\-\ undergo\\:\\ 0\\.10396111965327176\ \(0\)\
\-\ papillary\\:\\ 0\\.1037430640498414\ \(0\)\
\-\ radioiodine\\:\\ 0\\.09911986208627682\ \(0\)\
\-\ cancer\\:\\ 0\\.09886715991920537\ \(0\)\
\-\ patient\\:\\ 0\\.09655588673542301\ \(0\)\
\-\ her\\:\\ 0\\.09273278704928586\ \(0\)\
\-\ guidelines\\:\\ 0\\.09010165984629175\ \(0\)\
\-\ she\\:\\ 0\\.08835888470679404\ \(0\)\
\-\ newly\\:\\ 0\\.0858276525420736\ \(0\)\
\-\ trimester\\:\\ 0\\.08482634971198096\ \(0\)\
\-\ ablation\\:\\ 0\\.08108345760630668\ \(0\)\
\-\ diagnosed\\:\\ 0\\.0806408749912824\ \(0\)\
\-\ asymmetry\\:\\ 0\\.07877173386926205\ \(0\)\
\-\ for\\:\\ 0\\.07873080873277544\ \(0\)\
\-\ may\\:\\ 0\\.07469638256931571\ \(0\)\
\-\ affecting\\:\\ 0\\.07465602211008099\ \(0\)\
\-\ to\\:\\ 0\\.07421613204181149\ \(0\)\
\-\ final\\:\\ 0\\.07280891580407886\ \(0\)\
\-\ procedures\\:\\ 0\\.07280891580407886\ \(0\)\
\-\ no\\:\\ 0\\.0724032938520055\ \(0\)\
\-\ requires\\:\\ 0\\.07188579713286218\ \(0\)\
\-\ tests\\:\\ 0\\.0710238584655179\ \(0\)\
\-\ differentiated\\:\\ 0\\.07085811717128304\ \(0\)\
\-\ during\\:\\ 0\\.0705130521341739\ \(0\)\
\-\ association\\:\\ 0\\.0667899452320108\ \(0\)\
\-\ time\\:\\ 0\\.06598517798347225\ \(0\)\
\-\ of\\:\\ 0\\.06535747197646437\ \(0\)\
\-\ if\\:\\ 0\\.06468263375291845\ \(0\)\
\-\ in\\:\\ 0\\.0646194853444075\ \(0\)\
\-\ must\\:\\ 0\\.06360077565576301\ \(0\)\
\-\ american\\:\\ 0\\.06332096883617731\ \(0\)\
\-\ report\\:\\ 0\\.06251593792779264\ \(0\)\
\-\ until\\:\\ 0\\.06175782938677452\ \(0\)\
\-\ pregnancy\\:\\ 0\\.0607353293892919\ \(0\)\
\-\ surgery\\:\\ 0\\.05985306769268846\ \(0\)\
\-\ intranodular\\:\\ 0\\.059344342297441746\ \(0\)\
\-\ negligible\\:\\ 0\\.059344342297441746\ \(0\)\
\-\ significanly\\:\\ 0\\.059344342297441746\ \(0\)\
\-\ taskforce\\:\\ 0\\.059344342297441746\ \(0\)\
\-\ moosa\\:\\ 0\\.059344342297441746\ \(0\)\
\-\ mazzaferri\\:\\ 0\\.059344342297441746\ \(0\)\
\-\ jcem\\:\\ 0\\.059344342297441746\ \(0\)\
\-\ printed\\:\\ 0\\.059344342297441746\ \(0\)\
\-\ welker\\:\\ 0\\.059344342297441746\ \(0\)\
\-\ orlov\\:\\ 0\\.059344342297441746\ \(0\)\
\-\ nodules\\:\\ 0\\.05896968204336478\ \(0\)\
\-\ pathology\\:\\ 0\\.05826276411985854\ \(0\)\
\-\ removal\\:\\ 0\\.05673034609122202\ \(0\)\
\-\ hemithyroidectomy\\:\\ 0\\.056706687230286344\ \(0\)\
\-\ blum\\:\\ 0\\.056706687230286344\ \(0\)\
\-\ second\\:\\ 0\\.05556126891498799\ \(0\)\
\-\ compilation\\:\\ 0\\.05483524117744921\ \(0\)\
\-\ lactation\\:\\ 0\\.05483524117744921\ \(0\)\
\-\ breast\\:\\ 0\\.053894025683454486\ \(0\)\
\-\ risk\\:\\ 0\\.053029221326873856\ \(0\)\
\-\ visibly\\:\\ 0\\.05219758611029381\ \(0\)\
\-\ prefers\\:\\ 0\\.05219758611029381\ \(0\)\
\-\ copyright\\:\\ 0\\.05219758611029381\ \(0\)\
\-\ wait\\:\\ 0\\.05119479619416778\ \(0\)\
\-\ with\\:\\ 0\\.050863962372530595\ \(0\)\
\-\ is\\:\\ 0\\.050811879200667646\ \(0\)\
\-\ revised\\:\\ 0\\.05032614005745668\ \(0\)\
\-\ decide\\:\\ 0\\.04955993104313841\ \(0\)\
\-\ proceed\\:\\ 0\\.048874533724243004\ \(0\)\
\-\ highlights\\:\\ 0\\.04825451643129926\ \(0\)\
\-\ differences\\:\\ 0\\.04825451643129926\ \(0\)\
\-\ frozen\\:\\ 0\\.047688484990301275\ \(0\)\
\-\ updated\\:\\ 0\\.04668569507417525\ \(0\)\
\-\ and\\:\\ 0\\.04600792667860137\ \(0\)\
\-\ irradiation\\:\\ 0\\.04581703893746414\ \(0\)\
\-\ february\\:\\ 0\\.04581703893746414\ \(0\)\
\-\ discovery\\:\\ 0\\.04542266014202451\ \(0\)\
\-\ appointment\\:\\ 0\\.04505082992314587\ \(0\)\
\-\ radioactive\\:\\ 0\\.0446991087089187\ \(0\)\
\-\ carcinoma\\:\\ 0\\.044393084520798425\ \(0\)\
\-\ worked\\:\\ 0\\.044365432604250465\ \(0\)\
\-\ january\\:\\ 0\\.04404804000701985\ \(0\)\
\-\ elective\\:\\ 0\\.04374541531130672\ \(0\)\
\-\ fna\\:\\ 0\\.04345624513502198\ \(0\)\
\-\ microcalcifications\\:\\ 0\\.04345624513502198\ \(0\)\
\-\ intraoperative\\:\\ 0\\.0429138262710368\ \(0\)\
\-\ lobe\\:\\ 0\\.0428894190246359\ \(0\)\
\-\ one\\:\\ 0\\.042492553355191885\ \(0\)\
\-\ ultrasonography\\:\\ 0\\.04241317485599048\ \(0\)\
\-\ are\\:\\ 0\\.04224280208062947\ \(0\)\
\-\ decision\\:\\ 0\\.04217659395418271\ \(0\)\
\-\ iodine\\:\\ 0\\.04091355902203197\ \(0\)\
\-\ allows\\:\\ 0\\.04054172880315334\ \(0\)\
\-\ preferred\\:\\ 0\\.039385866934631024\ \(0\)\
\-\ without\\:\\ 0\\.03914652691896163\ \(0\)\
\-\ afp\\:\\ 0\\.03909012246993967\ \(0\)\
\-\ colloid\\:\\ 0\\.03880724060523659\ \(0\)\
\-\ fetus\\:\\ 0\\.03880724060523659\ \(0\)\
\-\ swallow\\:\\ 0\\.0386702827503162\ \(0\)\
\-\ remote\\:\\ 0\\.03840472515104426\ \(0\)\
\-\ this\\:\\ 0\\.03825329980289782\ \(0\)\
\-\ mets\\:\\ 0\\.038149584299914344\ \(0\)\
\-\ value\\:\\ 0\\.03778470785810051\ \(0\)\
\-\ longer\\:\\ 0\\.03778470785810051\ \(0\)\
\-\ 82\\:\\ 0\\.03778470785810051\ \(0\)\
\-\ superiorly\\:\\ 0\\.037328011055040494\ \(0\)\
\-\ case\\:\\ 0\\.03728567066627397\ \(0\)\
\-\ large\\:\\ 0\\.0371862584106915\ \(0\)\
\-\ ruled\\:\\ 0\\.03711114904624792\ \(0\)\
\-\ vascularity\\:\\ 0\\.03711114904624792\ \(0\)\
\-\ making\\:\\ 0\\.03711114904624792\ \(0\)\
\-\ up\\:\\ 0\\.03671221241015087\ \(0\)\
\-\ prenatal\\:\\ 0\\.03659865912415878\ \(0\)\
\-\ 67\\:\\ 0\\.03650083385476652\ \(0\)\
\-\ whether\\:\\ 0\\.036309488947874044\ \(0\)\
\-\ sites\\:\\ 0\\.0362158865009765\ \(0\)\
\-\ surgical\\:\\ 0\\.03607174452695575\ \(0\)\
\-\ probably\\:\\ 0\\.0360326276831608\ \(0\)\
\-\ tsh\\:\\ 0\\.03585439029193536\ \(0\)\
\-\ tc\\:\\ 0\\.03585439029193536\ \(0\)\
\-\ primarily\\:\\ 0\\.03559586920803275\ \(0\)\
\-\ reduced\\:\\ 0\\.03559586920803275\ \(0\)\
\-\ depending\\:\\ 0\\.035347230364265396\ \(0\)\
\-\ remaining\\:\\ 0\\.03526641866884254\ \(0\)\
\-\ nontender\\:\\ 0\\.034952851568825764\ \(0\)\
\-\ wnl\\:\\ 0\\.034801559684254156\ \(0\)\
\-\ feeding\\:\\ 0\\.034801559684254156\ \(0\)\
\-\ movement\\:\\ 0\\.03416118163032367\ \(0\)\
\-\ has\\:\\ 0\\.03390003299941931\ \(0\)\
\-\ definitive\\:\\ 0\\.03389562403105172\ \(0\)\
\-\ section\\:\\ 0\\.033830894563411\ \(0\)\
\-\ hx\\:\\ 0\\.03376680283488403\ \(0\)\
\-\ women\\:\\ 0\\.0333949726160054\ \(0\)\
\-\ 2003\\:\\ 0\\.0333949726160054\ \(0\)\
\-\ larger\\:\\ 0\\.033216735224779956\ \(0\)\
\-\ suspicious\\:\\ 0\\.033158391714197634\ \(0\)\
\-\ predominantly\\:\\ 0\\.03249626904562086\ \(0\)\
\-\ period\\:\\ 0\\.03244401769783806\ \(0\)\
\-\ pole\\:\\ 0\\.03234075746903522\ \(0\)\
\-\ local\\:\\ 0\\.031943366282791735\ \(0\)\
\-\ node\\:\\ 0\\.03189535678204689\ \(0\)\
\-\ component\\:\\ 0\\.031800387827881506\ \(0\)\
\-\ margins\\:\\ 0\\.03166048441808866\ \(0\)\
\-\ by\\:\\ 0\\.031516721640606385\ \(0\)\
\-\ so\\:\\ 0\\.03121474450038429\ \(0\)\
\-\ even\\:\\ 0\\.03121474450038429\ \(0\)\
\-\ do\\:\\ 0\\.03075731754885\ \(0\)\
\-\ smooth\\:\\ 0\\.03063795167095258\ \(0\)\
\-\ pending\\:\\ 0\\.030520736647042232\ \(0\)\
\-\ life\\:\\ 0\\.030443750448833223\ \(0\)\
\-\ measures\\:\\ 0\\.030255179047770295\ \(0\)\
\-\ gland\\:\\ 0\\.030144605431098048\ \(0\)\
\-\ 27\\:\\ 0\\.030071920229954592\ \(0\)\
\-\ denies\\:\\ 0\\.02992894177504437\ \(0\)\
\-\ increase\\:\\ 0\\.02978903836525152\ \(0\)\
\-\ references\\:\\ 0\\.029584667908882645\ \(0\)\
\-\ 19\\:\\ 0\\.029386522911059188\ \(0\)\
\-\ especially\\:\\ 0\\.02935407766761858\ \(0\)\
\-\ considered\\:\\ 0\\.028916058361432285\ \(0\)\
\-\ lymph\\:\\ 0\\.02885582406233943\ \(0\)\
\-\ additional\\:\\ 0\\.02876650561811544\ \(0\)\
\-\ uptake\\:\\ 0\\.028534150281785693\ \(0\)\
\-\ solid\\:\\ 0\\.028449113020884813\ \(0\)\
\-\ vs\\:\\ 0\\.02830980881505542\ \(0\)\
\-\ unknown\\:\\ 0\\.028119662481694604\ \(0\)\
\-\ previous\\:\\ 0\\.02803984236585215\ \(0\)\
\-\ at\\:\\ 0\\.028032592881519096\ \(0\)\
\-\ process\\:\\ 0\\.02783165634904268\ \(0\)\
\-\ malignancy\\:\\ 0\\.027780634457493996\ \(0\)\
\-\ 11\\:\\ 0\\.027780634457493996\ \(0\)\
\-\ management\\:\\ 0\\.027410216123118933\ \(0\)\
\-\ early\\:\\ 0\\.026748867843903786\ \(0\)\
\-\ mid\\:\\ 0\\.02670564338039175\ \(0\)\
\-\ later\\:\\ 0\\.02655658021433381\ \(0\)\
\-\ peripheral\\:\\ 0\\.026535561592414655\ \(0\)\
\-\ defined\\:\\ 0\\.026472910149971177\ \(0\)\
\-\ otherwise\\:\\ 0\\.026452159708693714\ \(0\)\
\-\ labs\\:\\ 0\\.02570901083133657\ \(0\)\
\-\ underwent\\:\\ 0\\.02556281910996206\ \(0\)\
\-\ left\\:\\ 0\\.025316940213917068\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.02526265899386723\ \(0\)\
\-\ although\\:\\ 0\\.02526265899386723\ \(0\)\
\-\ inflammatory\\:\\ 0\\.02509235456033515\ \(0\)\
\-\ followed\\:\\ 0\\.02505882222925975\ \(0\)\
\-\ palpation\\:\\ 0\\.025025461859612196\ \(0\)\
\-\ initial\\:\\ 0\\.02489370529850426\ \(0\)\
\-\ out\\:\\ 0\\.0243918462989316\ \(0\)\
\-\ known\\:\\ 0\\.024025049161793155\ \(0\)\
\-\ such\\:\\ 0\\.02386998692092344\ \(0\)\
\-\ some\\:\\ 0\\.023348217028894412\ \(0\)\
\-\ only\\:\\ 0\\.023183196762321466\ \(0\)\
\-\ negative\\:\\ 0\\.022973530494788914\ \(0\)\
\-\ years\\:\\ 0\\.022746926651581217\ \(0\)\
\-\ neck\\:\\ 0\\.022700210057096163\ \(0\)\
\-\ abdomen\\:\\ 0\\.02264228217810358\ \(0\)\
\-\ on\\:\\ 0\\.022414721893139596\ \(0\)\
\-\ cystic\\:\\ 0\\.022349101361849213\ \(0\)\
\-\ following\\:\\ 0\\.022261487137494578\ \(0\)\
\-\ lymphoma\\:\\ 0\\.022100324696282835\ \(0\)\
\-\ however\\:\\ 0\\.021963809029978642\ \(0\)\
\-\ cm\\:\\ 0\\.021311750709484326\ \(0\)\
\-\ low\\:\\ 0\\.021292976503597218\ \(0\)\
\-\ cell\\:\\ 0\\.021227690214024427\ \(0\)\
\-\ than\\:\\ 0\\.021035672880410583\ \(0\)\
\-\ who\\:\\ 0\\.020990777893217447\ \(0\)\
\-\ these\\:\\ 0\\.020955083659221246\ \(0\)\
\-\ patients\\:\\ 0\\.020875480598744084\ \(0\)\
\-\ symptoms\\:\\ 0\\.020303591203433387\ \(0\)\
\-\ soft\\:\\ 0\\.019755699919944473\ \(0\)\
\-\ woman\\:\\ 0\\.019326153962823243\ \(0\)\
\-\ diagnosis\\:\\ 0\\.019236709558780388\ \(0\)\
\-\ small\\:\\ 0\\.019141740604615\ \(0\)\
\-\ lower\\:\\ 0\\.0189624112691445\ \(0\)\
\-\ exam\\:\\ 0\\.018680365770838137\ \(0\)\
\-\ but\\:\\ 0\\.01835014081463019\ \(0\)\
\-\ after\\:\\ 0\\.018001872580727364\ \(0\)\
\-\ well\\:\\ 0\\.017968049673555725\ \(0\)\
\-\ presents\\:\\ 0\\.017851035457097812\ \(0\)\
\-\ treatment\\:\\ 0\\.017676679751972943\ \(0\)\
\-\ within\\:\\ 0\\.017090965216307364\ \(0\)\
\-\ normal\\:\\ 0\\.01515109358177636\ \(0\)\
\-\ as\\:\\ 0\\.014907744233103978\ \(0\)\
\-\ there\\:\\ 0\\.014765300319884218\ \(0\)\
\-\ from\\:\\ 0\\.014737866403317637\ \(0\)\
\-\ not\\:\\ 0\\.014649496860794933\ \(0\)\
\-\ or\\:\\ 0\\.012909336839586713\ \(0\)\
\-\ right\\:\\ 0\\.012302955930031983\ \(0\)\
\-\ year\\:\\ 0\\.01143606520773074\ \(0\)\
